SNY Sanofi
Company Analysis
Latest News
Sanofi secures EU approval for Cenrifki, first treatment for non-relapsing SPMS
The European Commission approved Sanofi’s drug Cenrifki (tolebrutinib) for adults with secondary progressive multiple sclerosis (SPMS) without recent relapses....
Sanofi Appoints Roche Veteran Paulo Fontoura as New Global Head of R&D
Sanofi has named Paulo Fontoura as its new Executive Vice President and Global Head of Pharma Research & Development, effective September 1, 2026. The...
Sanofi Reports Long-Term Riliprubart Gains in CIDP, Countering Phase 3 Setback
Sanofi reported new Phase 2 trial findings for riliprubart at the 2026 Peripheral Nerve Society Annual Meeting. Long-term treatment over 76 weeks led to...
Sanofi’s Tzield wins FDA approval for youth, slowing diabetes progression
The FDA granted accelerated approval for Sanofi’s Tzield (teplizumab-mzwv) for patients aged 8 to 17. This indication targets children and adolescents recently...
Sanofi Q1 2026 Earnings Preview: What Analysts Expect on April 23, 2026
Sanofi is expected to report Q1 2026 revenue of $11.99 billion and EPS of $1.04, with the stock currently trading near $48.06 compared to an average analyst...